Sign In
Buy ZYNE
$1.30
+0 (+0%)
At Close: Jan 09, 2024
Weed Stocks This Week: Major Earnings Blitz
01:51pm, Friday, 12'th Aug 2022
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks this week, and look ahead to how the cannabis industry will co
Zynerba Pharmaceuticals gets renewed 'Buy' rating, premium $11 price target from Canaccord Genuity after growth conference
12:54pm, Thursday, 11'th Aug 2022
Canaccord Genuity (TSX:CF, LSE:CF) analysts have reiterated a 'Buy' rating and issued an $11 price target for Zynerba Pharmaceuticals (NASDAQ:ZYNE) Inc in a note to clients. The brokerage firm rece
Zynerba Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights
11:00am, Wednesday, 10'th Aug 2022 GlobeNewswire Inc.
Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome (FXS); topline results expected second-half 2023
Zynerba Pharmaceuticals reports Q2 results and provides operational update
08:28am, Wednesday, 10'th Aug 2022
Zynerba Pharmaceuticals (NASDAQ:ZYNE) Inc has reported financial results for the second quarter ended June 30, 2022, and provided an overview of its recent operational highlights and a pipeline update
Zynerba Pharmaceuticals to Present In Person at the Canaccord Genuity 42nd Annual Growth Conference
11:00am, Wednesday, 03'rd Aug 2022 GlobeNewswire Inc.
DEVON, Pa., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsych
Zynerba Pharmaceuticals to Present In Person at the Canaccord Genuity 42nd Annual Growth Conference
07:00am, Wednesday, 03'rd Aug 2022
DEVON, Pa., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychia
Zynerba Pharmaceuticals enters into equity purchase agreement for up to $20M with Lincoln Park Capital
08:16am, Thursday, 21'st Jul 2022
Zynerba Pharmaceuticals (NASDAQ:ZYNE) Inc said it has entered into an equity purchase agreement for up to $20 million with Chicago-based institutional investor Lincoln Park Capital Fund LLC (LPC), in
Zynerba's Cannabidiol Formulated Gel Shows Encouraging Action In Genetic Disease
10:54am, Wednesday, 22'nd Jun 2022
Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) announced positive top-line results from the Phase 2 INSPIRE trial of Zygel (Transdermal CBD gel) on pediatric behavioral and emotional symptoms of 22q11.
Zynerba Pharmaceuticals reports positive results from Phase 2 trial of Zygel CBD gel in 22q11.2 Deletion Syndrome
08:01am, Wednesday, 22'nd Jun 2022
Zynerba Pharmaceuticals (NASDAQ:ZYNE) Inc has announced “very encouraging” data from a trial of its Zygel CBD gel for the treatment of 22q11.2 Deletion Syndrome (22q). The exploratory, open-labe
Zynerba Pharmaceuticals Announces Positive Top Line Results from Open-Label Phase 2 INSPIRE Trial of Zygel™ in 22q11.2 Deletion Syndrome
12:05am, Wednesday, 22'nd Jun 2022 GlobeNewswire Inc.
– The INSPIRE trial achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments –
3 Penny Stocks, Are They Worth Buying Right Now?
08:15pm, Thursday, 09'th Jun 2022 PennyStocks
Check these three penny stocks out for your watchlist right now
The post 3 Penny Stocks, Are They Worth Buying Right Now? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStoc
3 Penny Stocks, Are They Worth Buying Right Now?
04:15pm, Thursday, 09'th Jun 2022
Check these three penny stocks out for your watchlist right now The post 3 Penny Stocks, Are They Worth Buying Right Now? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStoc
Zynerba Pharmaceuticals Presents Data on Zygel™ at the American Society of Clinical Psychopharmacology Annual Meeting
11:00am, Wednesday, 01'st Jun 2022 GlobeNewswire Inc.
– Poster presentation highlights design enhancements incorporated into pivotal RECONNECT trial –
Zynerba Pharmaceuticals presents data on Zygel CBD gel at American Society of Clinical Psychopharmacology event this week
09:02am, Wednesday, 01'st Jun 2022
Zynerba Pharmaceuticals (NASDAQ:ZYNE) Inc said it will deliver oral and poster presentations on its CBD gel Zygel at the American Society of Clinical Psychopharmacology Annual Meeting (ASCP 2022), hel
Zynerba Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Highlights
11:00am, Monday, 16'th May 2022 GlobeNewswire Inc.
– Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome (FXS); topline results expected second-half 2023 –
